Feasibility of a Preoperative, Multimodal Lifestyle Intervention in Patients With Breastcancer
Recruiting now · Not applicable
Conditions studied: Breast Cancer, Breast Neoplasms
In brief
The primary objective of this study is to investigate the feasibility of a multimodal prehabilitation programme consisting of MIET during neoadjuvant intravenous chemotherapy infusion, HITT and strength training during the last six weeks prior to surgery, and optimising nutritional intake throughout the total preoperative period in patients with breast cancer with respect to recruitment, adherence, dropout, safety and acceptance. The secondary objective is to provide a preliminary evaluation of participant responses to a preoperative multimodal lifestyle intervention, on cardiorespiratory fitness, muscle strength, nutritional status, and fatigue in patients with breast cancer receiving neoadjuvant chemotherapy.
Key facts
- Study ID
- NCT06266312
- Run by
- Maastricht University Medical Center
- People needed
- 11
- Starts
- 2024-05-27
- Expected to finish
- 2025-11-01
- Last updated by the study team
- 2025-02-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients diagnosed with stage I-III breast cancer eligible for neoadjuvant intravenous chemotherapy at the MUMC+
- Aged ≥18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status Scale grade 0-1 (Table 1)
- Enough understanding of the Dutch language
You may not qualify if…
- Human Epidermal growth factor Receptor 2 (HER2) - positive tumour
- Scalp cooling
- Conditions that seriously hamper physical exercise
- Incapacitated subjects as reported by the attending medical specialist in the medical record. When any doubt arises, the patient will not be considered eligible.
Where it is running
- Maastricht University Medical Center — Maastricht, Limburg, Netherlands (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.